Biomica, a Rehovot, Israel-based clinical-stage biopharmaceutical company, raised $20M in funding.
The round was led by Shanghai Healthcare Capital. The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities.
The company intends to use the funds to develop its pipeline of microbiome-based therapeutics, complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial, scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), as well as advance additional programs.
Led by CEO Dr. Elran Haber, Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.
FinSMEs
22/12/2022